Importantly, on histological examination, we observed that anti-IL-23 treatment prevented the development of steatosis, ballooning, lobular inflammation, and reduced NAFLD scores in Atg5 CD11cKO mice when compared to isotype controls (Fig. 6i, j). This evidence concerns the gene ATG5 and metabolic dysfunction-associated steatotic liver disease.